MegaPro Biomedical

Hsinchu, Taiwan Founded: 2014 • Age: 12 yrs
Developer of niche-type nano-drugs for cancer

About MegaPro Biomedical

MegaPro Biomedical is a company based in Hsinchu (Taiwan) founded in 2014.. The company has 27 employees as of December 31, 2024. MegaPro Biomedical operates in a competitive market with competitors including Freeline, Imbed Biosciences, Disc Medicine, Alentis Therapeutics and Keros Therapeutics, among others.

  • Headquarter Hsinchu, Taiwan
  • Employees 27 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
    Technology
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Megapro Biomedical Co., Ltd.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Technology → Quantum & Emerging Technologies
Key Metrics
  • Annual Revenue
    $0 (USD)
    -22.22
    as on Dec 31, 2024
  • Net Profit
    $0 (USD)
    -28.61
    as on Dec 31, 2024
  • EBITDA
    $0 (USD)
    -31.58
    as on Dec 31, 2024
  • Latest Funding Round
  • Investors
  • Employee Count
    27

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of MegaPro Biomedical

MegaPro Biomedical is a publicly listed company on the TPEX with ticker symbol 6827 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: TPEX · Ticker: 6827 . Sector: Health technology · Taiwan

Funding Insights of MegaPro Biomedical

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by MegaPro Biomedical

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - MegaPro Biomedical

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Megapro Biomedical Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of MegaPro Biomedical

MegaPro Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Imbed Biosciences, Disc Medicine, Alentis Therapeutics and Keros Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Gene therapy platform is developed for chronic disease treatments.
domain founded_year HQ Location
Nanotech-based wound care products are developed and provided.
domain founded_year HQ Location
Developer of therapeutics for the treatment of hematologic diseases
domain founded_year HQ Location
Therapies for fibrosis, cirrhosis, and liver cancer are developed.
domain founded_year HQ Location
Small molecules are developed to treat hematologic and musculoskeletal disorders.
domain founded_year HQ Location
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Megapro Biomedical

Frequently Asked Questions about MegaPro Biomedical

When was MegaPro Biomedical founded?

MegaPro Biomedical was founded in 2014.

Where is MegaPro Biomedical located?

MegaPro Biomedical is headquartered in Hsinchu, Taiwan.

Who is the current CEO of MegaPro Biomedical?

Jassy Wang is the current CEO of MegaPro Biomedical.

How many employees does MegaPro Biomedical have?

As of Dec 31, 2024, the latest employee count at MegaPro Biomedical is 27.

What does MegaPro Biomedical do?

MegaPro Biomedical was founded in 2014 in Hsinchu, Taiwan, within the biotechnology sector. Proprietary PEGylated iron oxide nanoparticles, branded as IOP Injection, are developed as a contrast agent for magnetic resonance imaging. Additionally, this non-sugar-based intravenous iron formulation is targeted for iron-deficiency anemia and hepatocellular carcinoma treatments. Operations center on advancing these niche pharmaceutical applications through research and development.

Who are the top competitors of MegaPro Biomedical?

MegaPro Biomedical's top competitors include Imbed Biosciences, Keros Therapeutics and Disc Medicine.

Is MegaPro Biomedical publicly traded?

Yes, MegaPro Biomedical is publicly traded on TPEX under the ticker symbol 6827.

What is MegaPro Biomedical's ticker symbol?

The ticker symbol of MegaPro Biomedical is 6827 on TPEX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available